Meanwhile, Cantor Fitzgerald initiated its Redhill Biopharma Ltd. ADR [RDHL] rating to an Overweight in a research note published on August 31, 2021; the price target was $22. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in mid May with a ‘”a Buy”‘ rating. BTIG Research began covering RDHL with “Buy” recommendation on September 11, 2020. WBB Securities revised its rating on July 12, 2019. It rated RDHL as “a Strong buy” which previously was an “a Buy”.
Price Performance Review of RDHL
On Tuesday, Redhill Biopharma Ltd. ADR [NASDAQ:RDHL] saw its stock fall -5.50% to $1.89. Over the last five days, the stock has lost -2.07%. Redhill Biopharma Ltd. ADR shares have fallen nearly -69.57% since the year began. Nevertheless, the stocks have fallen -83.49% over the past one year. While a 52-week high of $20.27 was reached on 01/24/25, a 52-week low of $1.72 was recorded on 05/13/25. SMA at 50 days reached $2.48, while 200 days put it at $6.49.
Levels Of Support And Resistance For RDHL Stock
The 24-hour chart illustrates a support level at 1.72, which if violated will result in even more drops to 1.56. On the upside, there is a resistance level at 2.04. A further resistance level may holdings at 2.20. The Relative Strength Index (RSI) on the 14-day chart is 35.67, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.13, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 74.60%. Stochastics %K at 30.69% indicates the stock is a holding.
